Evidence map›Paper›PMID 34288921›Full record

ArticlePloS one2021

Molecular epidemiology of SARS-CoV-2 in Cyprus.

Jan Richter, Pavlos Fanis, Christina Tryfonos, Dana Koptides, George Krashias, Stavros Bashiardes, Andreas Hadjisavvas, Maria Loizidou, Anastasis Oulas, Denise Alexandrou and 4 more

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jan RichterMolecular Virology Department, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.ORCID 0000-0003-3737-7664
Pavlos FanisThe Cyprus School of Molecular Medicine, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Christina TryfonosMolecular Virology Department, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Dana KoptidesMolecular Virology Department, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
George KrashiasMolecular Virology Department, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Stavros BashiardesMolecular Virology Department, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Andreas HadjisavvasThe Cyprus School of Molecular Medicine, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Maria LoizidouThe Cyprus School of Molecular Medicine, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Anastasis OulasThe Cyprus School of Molecular Medicine, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Denise AlexandrouMedical and Public Health Services, Ministry of Health, Nicosia, Cyprus.
Olga KalakoutaMedical and Public Health Services, Ministry of Health, Nicosia, Cyprus.
Mihalis I PanayiotidisThe Cyprus School of Molecular Medicine, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.ORCID 0000-0002-1450-3552
George M SpyrouThe Cyprus School of Molecular Medicine, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Christina ChristodoulouMolecular Virology Department, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Whole genome sequencing of viral specimens following molecular diagnosis is a powerful analytical tool of molecular epidemiology that can critically assist in resolving chains of transmission, identifying of new variants or assessing pathogen evolution and allows a real-time view into the dynamics of a pandemic. In Cyprus, the first two cases of COVID-19 were identified on March 9, 2020 and since then 33,567 confirmed cases and 230 deaths were documented. In this study, viral whole genome sequencing was performed on 133 SARS-CoV-2 positive samples collected between March 2020 and January 2021. Phylogenetic analysis was conducted to evaluate the genomic diversity of circulating SARS-CoV-2 lineages in Cyprus. 15 different lineages were identified that clustered into three groups associated with the spring, summer and autumn/winter wave of SARS-CoV-2 incidence in Cyprus, respectively. The majority of the Cypriot samples belonged to the B.1.258 lineage first detected in September that spread rapidly and largely dominated the autumn/winter wave with a peak prevalence of 86% during the months of November and December. The B.1.1.7 UK variant (VOC-202012/01) was identified for the first time at the end of December and spread rapidly reaching 37% prevalence within one month. Overall, we describe the changing pattern of circulating SARS-CoV-2 lineages in Cyprus since the beginning of the pandemic until the end of January 2021. These findings highlight the role of importation of new variants through travel towards the emergence of successive waves of incidence in Cyprus and demonstrate the importance of genomic surveillance in determining viral genetic diversity and the timely identification of new variants for guiding public health intervention measures.

Indexed as

COVID-19CyprusHumansMolecular EpidemiologyPhylogenySARS-CoV-2

Identifiers

PMID34288921
PMCPMC8294526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.